Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Tertiary hyperparathyroidism (THPT) is characterized by over secretion of parathyroid hormone caused by long-standing secondary hyperparathyroidism. THPT can affect the bones as well as cause extraskeletal calcifications. The bony lesions often mimic multiple skeletal metastases or multiple myeloma. We report a case of a 48-year-old man with chronic kidney disease on dialysis, who presented with chief complaints of low back ache and swelling over the left clavicle. In view of clinical suspicion of malignancy with bony metastases, he underwent F-fluorodeoxyglucose positron emission tomography/computed tomography and was subsequently found to have parathyroid adenomas, which were confirmed on Tc-methoxy-isobutyl-isonitrile scintigraphy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10880846 | PMC |
| http://dx.doi.org/10.4103/ijnm.ijnm_12_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A study of tertiary hyperparathyroidism.
Ir J Med Sci
September 2025
Sri Venkateswara Institute of Medical Sciences, Tirupati, India.
Introduction: Information on tertiary hyperparathyroidism (THPTH) among chronic kidney disease (CKD) patients on haemodialysis in developing countries such as India is limited, and the mortality among them remains a query.
Materials And Methods: This was a prospective cohort study conducted in at a tertiary care centre from June 2017 to June 2022. The index of suspicion for tertiary hyperparathyroidism was when investigations revealed high serum calcium and high alkaline phosphatase along with new onset of body aches, joint pains, and difficulty in walking.
Brown Tumor: An Uncommon Manifestation of Severe Hyperparathyroidism.
Cureus
July 2025
Nephrology, Brookdale University Hospital Medical Center, Brooklyn, USA.
Brown tumor is now an uncommon form of osteitis fibrosa cystica. It results from an imbalance in bone remodeling, which leads to osteolytic lesions. This process, marked by microfractures and discoloration, is triggered by persistently elevated parathyroid hormone levels in end-stage renal disease (ESRD) patients with tertiary hyperparathyroidism.
View Article and Find Full Text PDFAge, gender, and BMI in presentation of primary hyperparathyroidism: a single-center experience.
Endokrynol Pol
September 2025
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Background: Primary hyperparathyroidism (PHPT) is a relatively common disease with considerable heterogeneity. We aimed to assess the impact of age, gender, and body mass index (BMI) on the presentation of PHPT.
Material And Methods: We retrospectively analyzed the baseline biochemical status, symptoms, renal manifestations, and bone mineral density (BMD) of patients diagnosed with PHPT at the national tertiary endocrine referral clinic from January 2004 to December 2016.
Clinicopathological insights into primary hyperparathyroidism: a comprehensive single-center retrospective study.
Endokrynol Pol
September 2025
Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Introduction: Primary hyperparathyroidism (PHPT) is caused by excessive hormone secretion from one or more parathyroid glands. Based on their morphological and immunophenotypic characteristics, parathyroid glands can be considered as neuroendocrine organs, and their neoplasms as neuroendocrine tumors. The 2022 World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors introduced updated diagnostic criteria, advancing the understanding of parathyroid neoplasms.
View Article and Find Full Text PDFSurgical management of renal hyperparathyroidism with total parathyroidectomy, autotransplantation, and cryopreservation with deferred autotransplantation: A 13-year experience.
J Pediatr Surg
August 2025
Pediatric Surgery and Urology Division, Hospital Italiano, Buenos Aires, Argentina.
Objective: Secondary and tertiary hyperparathyroidism in children with chronic kidney disease (CKD) require complex management. Surgical intervention aims to reduce parathyroid hormone (PTH) levels in CKD patients, thereby preventing complications associated with hyperparathyroidism (HPT). We describe our 13-year experience in the surgical management of secondary and tertiary hyperparathyroidism in pediatric patients, including total or subtotal parathyroidectomy, autoimplantation, cryopreservation, and deferred autoimplantation.
View Article and Find Full Text PDF